Foster City, Calif., June 20, 2024 – Today, Gilead announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women in sub-Saharan Africa.

In advance of today’s milestone and in view of the company’s ongoing commitment to communities affected by HIV, we have been developing a strategy to enable broad, sustainable access globally. A key component of this strategy is to deliver lenacapavir swiftly, sustainably and in sufficient volumes, if approved, to high-incidence, resource-limited countries, which are primarily low- and lower-middle-income countries... READ MORE